Bbt-401-1s (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04596293 (ClinicalTrials.gov) | January 31, 2021 | 15/10/2020 | Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis | A Randomised, Double-blind, Placebo-controlled Study of Orally Administered BBT-401-1S in Subjects With Moderate to Severe Ulcerative Colitis, Incorporating a Response-adaptive, Double-blind Extension Phase | Ulcerative Colitis | Drug: BBT-401-1S;Drug: Placebo | Bridge Biotherapeutics, Inc. | Covance | Not yet recruiting | 18 Years | 60 Years | All | 36 | Phase 2 | NULL |
| 2 | NCT04478825 (ClinicalTrials.gov) | October 30, 2020 | 16/7/2020 | Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | Ulcerative Colitis | Drug: BBT-401-1S | Bridge Biotherapeutics, Inc. | Covance | Recruiting | 18 Years | 60 Years | All | 6 | Phase 1 | New Zealand |
| 3 | NCT03800420 (ClinicalTrials.gov) | April 22, 2019 | 7/1/2019 | Efficacy and Safety of BBT-401-1S in Ulcerative Colitis | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis | Ulcerative Colitis | Drug: Active group;Drug: Placebo group | Bridge Biotherapeutics, Inc. | KCRN Research, LLC | Terminated | 18 Years | N/A | All | 16 | Phase 2 | United States |
| 4 | NCT03482648 (ClinicalTrials.gov) | March 20, 2018 | 17/3/2018 | First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Novel Oral Peptide BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Adult Subjects | Ulcerative Colitis | Drug: BBT-401-1S, Single dose;Drug: BBT-401-1S, Multiple doses;Drug: Placebo | Bridge Biotherapeutics, Inc. | KCRN Research, LLC | Completed | 19 Years | 55 Years | All | 80 | Phase 1 | United States |